Glen Rock, N.J., September 1, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, today announced that the Company is effecting the one-for-three-hundred–twenty-five reverse stock split of the Company’s issued and outstanding common stock (the…
Glen Rock, N.J., August 15, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its June 30, 2016 Quarterly Report on Form 10-Q and is hereby providing an update on the Company’s ongoing…
Glen Rock, N.J., July 12, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at…
Glen Rock, N.J., June 8, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present…
Glen Rock, N.J., May 16, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its March 31, 2016 Quarterly Report on Form 10-Q and is hereby providing an update on the Company’s ongoing…
Use of Ampakines as a Novel Therapy for Overcoming Central Respiratory Depression Glen Rock, N.J., April 1, 2016/Globe Newswire ? RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (?RespireRx? or the ?Company?), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, is providing an update on the Company?s collaborative research…
Provides Update on Current Operations and Plans for 2016 Glen Rock, N.J., March 29, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its December 31, 2015 Annual Report on Form 10-K and…
Glen Rock, N.J., March 11, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President and CEO, and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will…
Glen Rock, N.J., Feb. 29, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI as of January 11, 2016; previously OTC QB: CORX) (“RespireRx” or the “Company”), a leader in developing medicines for respiratory disorders, particularly sleep apnea and drug-induced respiratory depression, announced today that it has received notice that the U.S. Food and Drug…